Retatrutide Research Guide
A laboratory-focused overview of retatrutide structure, triple-receptor pharmacology, analytical testing, stability, body-composition research, and published clinical trial data.
Overview
Retatrutide, also known in development literature as LY3437943, is a synthetic peptide analog designed for activity at three related metabolic hormone receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. Because of this multi-target profile, it is commonly described as a triple hormone receptor agonist.
In research settings, retatrutide is of interest because simultaneous modulation of GIP, GLP-1, and glucagon signaling may influence metabolic regulation, energy balance, appetite signaling, glucose handling, lipid metabolism, and liver-fat-related endpoints.
Quick Reference
| Common name | Retatrutide |
|---|---|
| Development name | LY3437943 |
| Compound class | Synthetic modified peptide; triple incretin/glucagon receptor agonist |
| Primary research targets | GIP receptor, GLP-1 receptor, glucagon receptor |
| Research categories | Metabolic signaling, incretin biology, glucagon-family receptor pharmacology, obesity research, type 2 diabetes research, liver-fat and cardiometabolic investigation |
| Regulatory status | Investigational compound; not described here as FDA-approved for any use |
Mechanism and Receptor Biology
GLP-1 receptor pathway
The GLP-1 receptor is studied in glucose regulation, insulin secretion, gastric emptying, appetite signaling, and body-weight research. GLP-1 receptor agonism has become an important model for investigating how gut-derived peptide hormones influence metabolic physiology.
GIP receptor pathway
The GIP receptor is investigated for roles in insulin secretion, adipose tissue biology, lipid handling, and interaction with GLP-1 receptor signaling. Multi-agonist designs allow researchers to study whether GIP receptor activity modifies or complements GLP-1-associated effects.
Glucagon receptor pathway
The glucagon receptor is involved in hepatic glucose output, amino acid metabolism, lipid metabolism, and energy expenditure research. In multi-agonist peptide research, glucagon receptor activity is studied because it may affect energy-balance endpoints differently than GLP-1 or GIP receptor agonism alone.
Published Clinical Research
Clinical trial data can be included on a research library page when it is presented as factual scientific background, attributed to published literature or sponsor-reported results, and clearly separated from product sales copy. The following summaries are provided for scientific context only and should not be interpreted as human-use instructions or product claims.
Phase 2 obesity research
A randomized Phase 2 clinical trial published in the New England Journal of Medicine evaluated once-weekly retatrutide in adults with obesity or overweight. The study investigated multiple dose levels over a 48-week treatment period. Researchers reported dose-dependent reductions in body weight across treatment groups.
At 24 weeks, the highest evaluated dose group had an average body-weight reduction of approximately 17.5%. At 48 weeks, reported mean body-weight reductions included approximately 22.8% in the 8 mg group and 24.2% in the 12 mg group. Weight reduction was still progressing in several groups at the end of the study period, which is relevant when interpreting the duration of the trial.
Body-composition and fat-mass research
Body-composition analyses are important because total scale weight does not distinguish between fat mass, lean mass, and fluid changes. Retatrutide has been evaluated in body-composition research using imaging-based methods such as MRI or DEXA, depending on the study design.
In adults with type 2 diabetes, a published body-composition analysis reported dose-related reductions in total fat mass. Reported percent reduction from baseline in total fat mass included 4.9% with retatrutide 0.5 mg, 15.2% with pooled retatrutide 4 mg, and 26.1% with higher-dose retatrutide in the reported analysis. The authors also noted that the proportion of lean-mass loss relative to total weight loss was broadly similar to other obesity treatments.
For a neutral research summary, these findings are best described as body-composition observations rather than as a claim that retatrutide selectively preserves muscle or guarantees a specific fat-loss outcome.
Liver-fat research
A Phase 2a substudy published in Nature Medicine evaluated participants with metabolic dysfunction-associated steatotic liver disease and elevated liver-fat content. The substudy focused on relative change in liver fat over 24 weeks and reported substantial reductions in liver fat in retatrutide-treated groups. These findings are relevant to scientific questions involving hepatic lipid handling, metabolic liver biology, and cardiometabolic biomarkers.
Phase 3 TRIUMPH-1 obesity trial
In May 2026, Eli Lilly announced topline Phase 3 TRIUMPH-1 results in adults with obesity or overweight. According to the sponsor announcement, participants receiving 12 mg retatrutide had an average body-weight reduction of 70.3 pounds, or 28.3%, over 80 weeks, compared with 2.2% for placebo. The announcement also reported that 45.3% of participants in the 12 mg group achieved at least 30% body-weight reduction.
The same announcement reported that individuals with baseline BMI of at least 35 who participated in a study extension continued to lose weight and achieved an average 85.0-pound, or 30.3%, body-weight reduction at 104 weeks. These data were sponsor-reported topline results and should be interpreted alongside complete peer-reviewed publications when available.
Phase 3 TRANSCEND-T2D-1 type 2 diabetes trial
In March 2026, Eli Lilly announced topline Phase 3 results from TRANSCEND-T2D-1. The company reported that retatrutide lowered A1C by an average of 1.7 to 2.0 percentage points across evaluated doses at 40 weeks. In the 12 mg group, the sponsor reported an average body-weight reduction of 36.6 pounds, or 16.8%.
Phase 3 TRIUMPH-4 obesity and knee osteoarthritis trial
In December 2025, sponsor-reported Phase 3 TRIUMPH-4 results described retatrutide research in participants with obesity and knee osteoarthritis. Reported findings included average body-weight reduction up to 28.7% at 68 weeks in the 12 mg group. Reports also described improvement in WOMAC pain scores. As with other topline data, complete peer-reviewed datasets are needed for full interpretation.
Safety observations in clinical research
Across published and sponsor-reported retatrutide studies, the most commonly described adverse events were gastrointestinal in nature, including nausea, vomiting, diarrhea, constipation, and decreased appetite. These events were often reported during dose-escalation periods. Safety observations should be presented neutrally and should not be converted into dosing guidance, administration recommendations, or claims of clinical suitability.
Research Applications and Areas of Investigation
Retatrutide-related research generally falls into metabolic signaling, body-weight models, appetite and energy-balance research, liver-fat research, glycemic-control research, body-composition research, and comparative incretin research. It is often compared conceptually with GLP-1-only analogs and dual agonists because it incorporates a third receptor pathway.
Analytical Testing
HPLC purity
High-performance liquid chromatography is commonly used to estimate peptide purity. The main peak in a chromatogram represents the dominant detected component under the method conditions. Secondary peaks may represent related impurities, deletion sequences, oxidation products, or degradation products.
Mass confirmation
LC-MS or another mass-based method may be used to compare the observed molecular mass with the expected molecular mass. For modified peptides, identity confirmation is especially important because the expected mass reflects both the amino acid sequence and any designed structural modifications.
COA interpretation
A batch-specific Certificate of Analysis should identify the compound, lot number, analytical method, purity result, identity-confirmation method when available, appearance, and testing date. COA documentation supports traceability but does not replace internal laboratory validation.
Stability and Laboratory Handling
Research peptides are commonly supplied as lyophilized powders because reduced water content can improve storage stability. Peptide integrity may still be affected by temperature, moisture, oxygen exposure, light, pH, concentration, and repeated freeze-thaw cycling.
General laboratory handling principles include minimizing moisture exposure, using clean technique, protecting material from unnecessary heat and light, keeping clear batch records, and following validated internal procedures for preparation and storage.
Frequently Asked Questions
What is retatrutide?
Retatrutide is an investigational modified peptide analog studied as a triple agonist of GIP, GLP-1, and glucagon receptors.
Is retatrutide the same as semaglutide?
No. Semaglutide is primarily a GLP-1 receptor agonist. Retatrutide is studied for activity across GIP, GLP-1, and glucagon receptor systems.
What did Phase 2 research report?
The Phase 2 obesity trial reported dose-dependent body-weight reductions, including approximately 24.2% mean body-weight reduction at 48 weeks in the 12 mg group.
What did Phase 3 topline results report?
Sponsor-reported TRIUMPH-1 topline results described an average 28.3% body-weight reduction at 80 weeks with 12 mg retatrutide and 45.3% of participants achieving at least 30% body-weight reduction.
Does the research distinguish fat mass from lean mass?
Body-composition research has reported dose-related total fat-mass reductions. Lean-mass changes should be discussed cautiously because body-composition outcomes depend on study population, imaging method, trial duration, and analysis approach.
Is this medical advice?
No. This page is educational content for laboratory research contexts only.
References and Further Reading
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
- Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine. 2024.
- Coskun T et al. Effects of retatrutide on body composition in people with type 2 diabetes. The Lancet Diabetes & Endocrinology. 2025.
- Eli Lilly and Company. TRIUMPH-1 Phase 3 topline results announcement. 2026.
- Eli Lilly and Company. TRANSCEND-T2D-1 Phase 3 topline results announcement. 2026.
- Eli Lilly and Company. TRIUMPH-4 Phase 3 topline results announcement. 2025.
- ClinicalTrials.gov retatrutide trial records.
